Power Law company profile

2seventybio

Biotech & Life Sciences · Cambridge, United States · Founded 2021 · IPO 2021 Thoroughbred

Immuno-oncology cell therapy company that discovers and develops therapies used for cancer treatment

Valuation

$100–500M

Latest valuation · 2026

Unlock exact value

Revenue

$10–50M

Latest reported FY

Unlock exact value

Headcount

<100

Current team size

Unlock exact value

Featured in $10B+ revenueThoroughbred · Power Law outcome

Investors

11 investors on 2seventybio's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 11 investors entered at this stage

Janus Henderson Investors

EcoR1 Capital

Cowen Healthcare Investments

683 Capital

Boxer Capital

Heights Capital Management

Bain Capital Life Sciences

RTW Investments

Casdin Capital

CaaS Capital Management

Armistice Capital

Global footprint

Where 2seventybio has talent and traffic

Workforce by country

1 countries with
team presence

🇺🇸 United States100%

1 country shown

Web traffic by country

920 monthly visits
across markets

🇺🇸 United States97.8%

Top 1 markets shown

Market sentiment

What the market is saying about 2seventybio

An AI-synthesized read of the highest-engagement posts about 2seventybio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See 2seventybio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles